Abstract
Loss of p53 function is one of the most frequent genetic alterations in human cancers. Both replication-incompetent (rAd.p53, or SCH58500) and replication-selective (dl1520, or Onyx-015) adenoviruses are being developed for the treatment of p53-deficient cancers. Hepatic arterial infusion (HAI) has historically been used to selectively target colorectal tumors within the liver; consequently, regional therapy with adenovirus in this setting is an attractive approach. This article reviews Phase I and I/II HAI trial results with these adenovirus constructs.
MeSH terms
-
Adenoviridae / genetics*
-
Animals
-
Clinical Trials, Phase I as Topic
-
Clinical Trials, Phase II as Topic
-
Colorectal Neoplasms / pathology*
-
Dose-Response Relationship, Drug
-
Drug Evaluation, Preclinical
-
Gene Transfer Techniques* / adverse effects
-
Gene Transfer Techniques* / trends
-
Genes, p53 / genetics*
-
Genetic Therapy / adverse effects
-
Genetic Therapy / methods*
-
Genetic Therapy / trends
-
Genetic Vectors / therapeutic use*
-
Hepatic Artery
-
Humans
-
Infusions, Intra-Arterial
-
Liver Neoplasms / genetics
-
Liver Neoplasms / mortality
-
Liver Neoplasms / secondary*
-
Liver Neoplasms / therapy*
-
Maximum Tolerated Dose
-
Viral Vaccines / pharmacokinetics
-
Viral Vaccines / therapeutic use*